Xcout IntelEton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Subscribe to see Eton Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Eton Pharmaceuticals, Inc. at a glance
Eton Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in Deer Park, United States. It is publicly listed (ETON) with a market capitalisation of $1.6B. Xcout tracks 14 named people at Eton Pharmaceuticals, Inc., including Sean E. Brynjelsen (President, Chief Executive Officer & Director).
Eton Pharmaceuticals, Inc. leadership
- Sean E. BrynjelsenPresident, Chief Executive Officer & Director
- Sean BrynjelsenChief Executive Officer & Director
- Danka RadosavljevicChief Operating Officer
- Judith MatthewsChief Financial Officer & Secretary
- Judy MatthewsChief Financial Officer
- David KrempaChief Business Officer
8 more named people on record for Eton Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Eton Pharmaceuticals, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $20.1M | — |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Eton Pharmaceuticals, Inc. competitors
A few of Eton Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Egetis Therapeutics is a specialty pharmaceutical company that develops and commercializes treatments for serious, rare diseases with high unmet medical need. Its lead product is Emcitate (tiratricol), a treatment for MCT8 deficiency. The company serves patients, caregivers, and healthcare professionals.
ResQ Pharma, Inc. is a specialty pharmaceutical company founded in 2015 and headquartered in Glenview, Illinois, focused on providing reliable access to life-saving lipid-based therapies such as LipidRescue.
Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company that develops and markets cortisol modulation therapies to treat serious medical conditions. The company focuses on modulating cortisol activity at the glucocorticoid receptor to create novel treatments across therapeutic areas such as endocrinology, oncology, metabolism, and neurology.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare and orphan diseases.
Get Eton Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Eton Pharmaceuticals, Inc. in Xcout Intel
- 14 named people with titles, LinkedIn and board committees
- 1 funding round before the IPO with the investors in each, and who they co-invest with
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access